This Biotech Company Added Nearly $3B To Its Market Cap Today — Here’s Why KOD Stock Is Ripping Today

Shares of Kodiak Sciences (KOD) more than doubled after the opening bell on Monday as both of its experimental therapies met the primary goal of a Phase 3 study in patients with wet age-related macular degeneration.Wet AMD is an eye disease in which abnormal blood vessels grow under the retina and…